Marth C - Search Results

1

Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology.

Marth C, Hiebl S, Oberaigner W, Winter R, Leodolter S, Sevelda P. Marth C, et al. Int J Gynecol Cancer. 2009 Jan;19(1):94-102. doi: 10.1111/IGC.0b013e31819915cb. Int J Gynecol Cancer. 2009. PMID: 19258949

2

In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.

Dittrich C, Sevelda P, Baur M, Marth C, Hudec M, Vavra N, Grunt T, Fazeny B, Salzer H. Dittrich C, et al. Among authors: marth c. Cancer. 1993 May 15;71(10):3082-90. doi: 10.1002/1097-0142(19930515)71:10<3082::aid-cncr2820711031>3.0.co;2-6. Cancer. 1993. PMID: 8490836 Clinical Trial.

3

Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer.

Zeimet AG, Natoli C, Herold M, Fuchs D, Windbichler G, Daxenbichler G, Iacobelli S, Dapunt O, Marth C. Zeimet AG, et al. Among authors: marth c. Int J Cancer. 1996 Sep 27;68(1):34-8. doi: 10.1002/(SICI)1097-0215(19960927)68:1<34::AID-IJC7>3.0.CO;2-Y. Int J Cancer. 1996. PMID: 8895537

4

High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.

Zeimet AG, Widschwendter M, Uhl-Steidl M, Müller-Holzner E, Daxenbichler G, Marth C, Dapunt O. Zeimet AG, et al. Among authors: marth c. Br J Cancer. 1997;76(12):1646-51. doi: 10.1038/bjc.1997.611. Br J Cancer. 1997. PMID: 9413956 Free PMC article.

5

Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.

Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Müller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C. Zeimet AG, et al. Among authors: marth c. J Clin Oncol. 1998 May;16(5):1861-8. doi: 10.1200/JCO.1998.16.5.1861. J Clin Oncol. 1998. PMID: 9586902

6

Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.

Abendstein B, Marth C, Müller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG. Abendstein B, et al. Among authors: marth c. Cancer. 2000 Mar 15;88(6):1432-7. doi: 10.1002/(sici)1097-0142(20000315)88:6<1432::aid-cncr22>3.0.co;2-8. Cancer. 2000. PMID: 10717627

7

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.

Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C. Windbichler GH, et al. Among authors: marth c. Br J Cancer. 2000 Mar;82(6):1138-44. doi: 10.1054/bjoc.1999.1053. Br J Cancer. 2000. PMID: 10735496 Free PMC article. Clinical Trial.

8

Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis.

Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø. Marth C, et al. Cancer. 2002 Feb 1;94(3):707-12. doi: 10.1002/cncr.10250. Cancer. 2002. PMID: 11857303 Free article.

9

CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.

Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, Müller-Holzner E, Goebel G, Marth C, Widschwendter M. Widschwendter A, et al. Among authors: marth c. Int J Cancer. 2004 Mar 20;109(2):163-6. doi: 10.1002/ijc.11706. Int J Cancer. 2004. PMID: 14750164

10

DNA hypomethylation and ovarian cancer biology.

Widschwendter M, Jiang G, Woods C, Müller HM, Fiegl H, Goebel G, Marth C, Müller-Holzner E, Zeimet AG, Laird PW, Ehrlich M. Widschwendter M, et al. Among authors: marth c. Cancer Res. 2004 Jul 1;64(13):4472-80. doi: 10.1158/0008-5472.CAN-04-0238. Cancer Res. 2004. PMID: 15231656

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

495 results

Search Page

Filters